Fluvastatin-Pretreated Donor Cells Attenuated Murine aGVHD by Balancing Effector T Cell Distribution and Function under the Regulation of KLF2

Figure 2

Transferring with Fluvastatin-pretreated donor cells improved the general conditions and alleviated tissue pathological injury in recipient after transplantation. (a) Body weight changes were quantified and clinical score including hair loss, posture, mobility, and diarrhea were assessed in recipients at series of time points posttransplantation. (b) Recipients were monitored and were sacrificed on different days. Pathological score of recipient target organs (liver, lung, and guts) were measured by HE stating and (c) HE photographs (×200) of recipient target tissue slices from each group on 28 days after transplantation were shown. Data represents the of results from 3 independent experiments. Mice were included for serial time point detections in GVHD with or without Fluvastatin-pretreated donor cells in every repeated experiment (), respectively. TBI or unmanipulated groups were used as control (). , , n.s .

(a)

(b)

(c)